Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I wonder if ACUT are killing time for this?
https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5500-series
'5505. Initial Listing of Primary Equity Securities
A Company applying to list its Primary Equity Security on the Capital Market must meet all of the requirements set forth in Rule 5505(a) and at least one of the Standards in Rule 5505(b).
(a) Initial Listing Requirements for Primary Equity Securities:
(1) (A) Minimum bid price of $4 per share; or
(B) Minimum closing price of $3 per share, if the Company meets the requirements of the Equity or Net Income Standards under Rules 5505(b)(1) or (b)(3), or of $2 per share, if the Company meets the requirements of the Market Value of Listed Securities Standard under Rule 5505(b)(2), provided that in either case the Company must also demonstrate that it has net tangible assets (i.e., total assets less intangible assets and liabilities) in excess of $2 million, if the issuer has been in continuous operation for at least three years; or net tangible assets in excess of $5 million, if the issuer has been in continuous operation for less than three years; or average revenue of at least $6 million for the last three years. A security must meet the applicable closing price requirement for at least five consecutive business days prior to approval.'
I doubt it
Am liking this. Life in the old dog yet and may well see the returns we all hoped for.....one day.
https://finance.yahoo.com/news/accustem-sciences-announces-extension-us-110000500.html
'GlobeNewswire
AccuStem Sciences Announces Extension of its US Patent Application for SPARE Test for Patients with Breast Cancer
AccuStem Sciences, Inc.
Tue, May 2, 2023, 12:00 PM GMT+1'
78.5c last time I looked.
Perhaps time for Accustem to float on NASDAQ?
Tiziana and accustem been heading in polar opposite directions over last fortnight with plenty buying the latter. Wonder why?
Looks like someone has been buying up over the last week or so.
Jenn- harsh, but most likely true.
Hum, tils at 40p in old money. expect another fund raise with a stock split again! Back to under 50c 25p in old money for another year until the $1 10 day rule, if the co still exist by then! Listing overseas has been a disaster for PIs.
Just been clearing out my drawers and found two share certificates from the good old days of the Tiziana/Accustem split.
I have a certificate from link group for 1158 shares in Accustem Sciences Limited, and a certificate from Accustem themselves for 57 "book entry" shares.
I think I'm right in saying the only shares with any value are the shares in ACUT? And given that 58 shares is worth about £70, it's hardly worth going through the hassle of getting them into my portfolio.
Can anyone shed any light? It's been a long time.
Bo - were you not tempted to sell last week given your frustrations here.
Having seen this rise to over a dollar , gain NASDAQ compliance and then fall back to the .5s last year, for me it was too risky seeing it do it all over again. After a 100% rise in just a couple of weeks I sold out with a hefty loss just under $1.20, as it seemed all too likely that the rise was ‘manufactured’ in order to get back in line with listing rules.
I would have thought you might be tempted to do the same rather than suffer the pain of it dropping back again. For holders sake I hope this doesn’t drift all the way back to the .6 / .5 levels again and be back in the same position all over again.
Also, with all the trials they are wanting to do, I can see their spend increasing more than the last years...hla
Ask yourself this, do you think shareholders have seen 19 million dollars worth of value in the last year? 19 million?
R&d expenses $13 million, where has the other 6 gone! This just REEKS of lifestyle company I actually LAUGH when I read the RNS now it strikes me as that much of a made up fairytale or new BS every week
https://www.tizianalifesciences.com/news-item?s=2023-04-26-tiziana-life-sciences-ltd-reports-annual-results-for-the-twelve-months-ended-december-31-2022-and-corporate-update&preview=all
$18m cash left at the end of 2022. Given cash burn is about that on annual basis, it’s likely they’ll need to raise cash before year end. Unless they manage to secure a licensing agreement
On the plus side accustem still heading north.
Dieing a really quick death!.
Nasdaq compliance notice on the Friday and deficiency notice on the Tuesday?
Hilarious
Share price closed below $1 last night.
Plus a fat annual salary and holiday packages. life is rosy
It seems like a lifestyle company in all honesty, if they believed in the assets they would be shouting from the rooftops, but they only do that when they need a placing, which makes sense because you can milk $25-50M in placings every 2-3 years for the next 20 years which is way more fruitful than to develop and sell the company for one big lump sum
Excellent news. Now will the SP collapse back to $0.50 level or will this be a foothold to move back to an MCAP that we’re more comfortable with.
Accustem, will it ever uplist to the Nasdaq?
The absolute front they have to refuse to discuss it and tell investors “that’s a separately listed company” etc.
Over 900 days since the ex date, current MCAP $12.5m dollars traded OTC as a penny stock. A far cry from the valuation by HC Wainwright (I think it was them)
“ Accustem may be publicly listed upon completion of the spinout; its valuation could be fairly reckoned at $280M—10% of the valuation placed upon Genomic Health at the time of its acquisition by EXACT Sciences last year.”
WHAT IS GOING ON
Bo, In my account with ii, I have both tils shares and accustem shares listed with a price in USD. I an down around 60% but at least i have the holdings and can trade them. If you have not got yours chase youe broker.
You’ll find it’s an issue with the brokers, not the company.
Most brokers have managed to get their house in order.
No scam here, good times ahead ;)
Isn’t it right some people still haven’t got their shares??
Unbelievable.
How long until Nasdaq uplisting? Is it still happening? Can someone please say something about Accustem?
Please BOD, if you’re reading this, UPDATE INVESTORS ABOUT ACCUSTEM.
Paul, I don’t want to hear “they’ve already said XYZ”, they’ve been saying it for years.
If they are still planning on uplisting, keep investors informed.